Biocon Bets Big on Insulin, Eyes GLP-1 Drugs for Future Growth

Bengaluru – Biocon Biologics, the biopharmaceutical arm of Biocon Ltd, is strengthening its foothold in the global insulin market while making a decisive move into the booming GLP-1 drug segment.…

  • Pharma
  • May 14, 2025
  • 454 views
India’s anti-obesity drug market quadruples in five years on lifestyle disease surge

India’s anti-obesity drug market has grown more than fourfold in the last five years fuelled by rising instances of lifestyle diseases along with greater affordability and willingness among a section…

  • Pharma
  • April 24, 2025
  • 631 views
Novo Nordisk to phase out country’s largest insulin brand

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, Human Mixtard, among other older insulin brands in India. Human Mixtard…

  • Pharma
  • March 19, 2025
  • 437 views
Novo Nordisk regains membership in UK pharma body

London: Danish pharmaceutical giant Novo Nordisk has regained its membership in the UK’s pharmaceutical industry body after serving a two-year suspension for breaching a national drugmakers practice code. The Association of the British…